Cellectis plant Phase 1 study of.HEAL-101 in China
Cellectis plans a Phase 1 study of.HEAL-101 for severe hypertriglyceridemia in China.
Related stories
Haitian Flavoring's Q3 net profit falls more than a tenth
Haitian Flavoring reported third-quarter revenue of 64.1 hundred-million yuan, nearly flat year over year. The headline says net profit fell by more than a tenth.
M impact | EQUITY | Oct 29, 2026, 09:56 AM UTC
Axis REIT Reports Third-Quarter 2026 Results
Axis REIT reported revenue of MYR 90,779,000 and pretax profit of MYR 54,798,000 for the quarter ended September 30, 2026. Revenue was MYR 92,767,000 and pretax profit was MYR 52,1
M impact | EQUITY | Oct 29, 2026, 09:56 AM UTC
Ningbo Zhoushan Port Q3 Net Profit Falls 17.16% Y/Y
M impact | EQUITY | Oct 29, 2026, 09:56 AM UTC
Schneider Electric Infrastructure to Expand Vacuum Interrupter Capacity
Schneider Electric Infrastructure plans to increase vacuum interrupter capacity from 250,000 to 375,000 units per annum.
M impact | EQUITY | Oct 29, 2026, 09:55 AM UTC
Acwa-EIG Joint Venture Targets $4 Billion Investment in US Power Sector
Saudi Arabia’s Acwa said its joint venture with EIG targets $4 billion in investment in the US power sector.
M impact | EQUITY | Oct 29, 2026, 09:55 AM UTC
Montage Technology Says Q3 Revenue Rose 46% Year Over Year
M impact | EQUITY | Oct 29, 2026, 09:55 AM UTC